187 related articles for article (PubMed ID: 8891169)
1. Transient protection of human T-cells from human immunodeficiency virus type 1 infection by transduction with adeno-associated viral vectors which express RNA decoys.
Smith C; Lee SW; Wong E; Gallardo H; Page K; Gaspar O; Lebkowski J; Gilboa E
Antiviral Res; 1996 Oct; 32(2):99-115. PubMed ID: 8891169
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of human immunodeficiency virus type 1 in human T cells by a potent Rev response element decoy consisting of the 13-nucleotide minimal Rev-binding domain.
Lee SW; Gallardo HF; Gilboa E; Smith C
J Virol; 1994 Dec; 68(12):8254-64. PubMed ID: 7966618
[TBL] [Abstract][Full Text] [Related]
3. Transduction of human CD34+ hematopoietic progenitor cells by a retroviral vector expressing an RRE decoy inhibits human immunodeficiency virus type 1 replication in myelomonocytic cells produced in long-term culture.
Bahner I; Kearns K; Hao QL; Smogorzewska EM; Kohn DB
J Virol; 1996 Jul; 70(7):4352-60. PubMed ID: 8676458
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of HIV-1 in CEM cells by a potent TAR decoy.
Lee SW; Gallardo HF; Gaspar O; Smith C; Gilboa E
Gene Ther; 1995 Aug; 2(6):377-84. PubMed ID: 7584112
[TBL] [Abstract][Full Text] [Related]
5. High level inhibition of HIV replication with combination RNA decoys expressed from an HIV-Tat inducible vector.
Fraisier C; Irvine A; Wrighton C; Craig R; Dzierzak E
Gene Ther; 1998 Dec; 5(12):1665-76. PubMed ID: 10023446
[TBL] [Abstract][Full Text] [Related]
6. A combination anti-HIV-1 gene therapy approach using a single transcription unit that expresses antisense, decoy, and sense RNAs, and trans-dominant negative mutant Gag and Env proteins.
Ding SF; Lombardi R; Nazari R; Joshi S
Front Biosci; 2002 Feb; 7():a15-28. PubMed ID: 11815282
[TBL] [Abstract][Full Text] [Related]
7. Potent inhibition of human immunodeficiency virus type 1 in primary T cells and alveolar macrophages by a combination anti-Rev strategy delivered in an adeno-associated virus vector.
Inouye RT; Du B; Boldt-Houle D; Ferrante A; Park IW; Hammer SM; Duan L; Groopman JE; Pomerantz RJ; Terwilliger EF
J Virol; 1997 May; 71(5):4071-8. PubMed ID: 9094685
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of human immunodeficiency virus type 1 by Tat/Rev-regulated expression of cytosine deaminase, interferon alpha2, or diphtheria toxin compared with inhibition by transdominant Rev.
Ragheb JA; Couture L; Mullen C; Ridgway A; Morgan RA
Hum Gene Ther; 1999 Jan; 10(1):103-12. PubMed ID: 10022535
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of human immunodeficiency virus type 1 replication by regulated expression of a polymeric Tat activation response RNA decoy as a strategy for gene therapy in AIDS.
Lisziewicz J; Sun D; Smythe J; Lusso P; Lori F; Louie A; Markham P; Rossi J; Reitz M; Gallo RC
Proc Natl Acad Sci U S A; 1993 Sep; 90(17):8000-4. PubMed ID: 8367455
[TBL] [Abstract][Full Text] [Related]
10. Decoy approach using RNA-DNA chimera oligonucleotides to inhibit the regulatory function of human immunodeficiency virus type 1 Rev protein.
Nakaya T; Iwai S; Fujinaga K; Sato Y; Otsuka E; Ikuta K
Antimicrob Agents Chemother; 1997 Feb; 41(2):319-25. PubMed ID: 9021186
[TBL] [Abstract][Full Text] [Related]
11. Combination gene therapy: synergistic inhibition of human immunodeficiency virus Tat and Rev functions by a single RNA molecule.
Lisziewicz J; Zeng G; Gratas C; Weinstein JN; Lori F
Hum Gene Ther; 2000 Apr; 11(6):807-15. PubMed ID: 10779158
[TBL] [Abstract][Full Text] [Related]
12. Down-modulation of TCR/CD3 surface complexes after HIV-1 infection is associated with differential expression of the viral regulatory genes.
Willard-Gallo KE; Furtado M; Burny A; Wolinsky SM
Eur J Immunol; 2001 Apr; 31(4):969-79. PubMed ID: 11298321
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of human immunodeficiency virus type 1 (HIV-1) replication by HIV-1-based lentivirus vectors expressing transdominant Rev.
Mautino MR; Keiser N; Morgan RA
J Virol; 2001 Apr; 75(8):3590-9. PubMed ID: 11264348
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of human immunodeficiency virus-1 (HIV-1) replication after transduction of granulocyte colony-stimulating factor-mobilized CD34+ cells from HIV-1-infected donors using retroviral vectors containing anti-HIV-1 genes.
Bauer G; Valdez P; Kearns K; Bahner I; Wen SF; Zaia JA; Kohn DB
Blood; 1997 Apr; 89(7):2259-67. PubMed ID: 9116267
[TBL] [Abstract][Full Text] [Related]
15. Long-term protection against HIV-1 infection conferred by tat or rev antisense RNA was affected by the design of the retroviral vector.
Peng H; Callison D; Li P; Burrell C
Virology; 1996 Jun; 220(2):377-89. PubMed ID: 8661389
[TBL] [Abstract][Full Text] [Related]
16. Anti-HIV effects of HIV vectors.
Corbeau P; Wong-Staal F
Virology; 1998 Apr; 243(2):268-74. PubMed ID: 9568026
[TBL] [Abstract][Full Text] [Related]
17. Overexpression of RRE-derived sequences inhibits HIV-1 replication in CEM cells.
Lee TC; Sullenger BA; Gallardo HF; Ungers GE; Gilboa E
New Biol; 1992 Jan; 4(1):66-74. PubMed ID: 1536832
[TBL] [Abstract][Full Text] [Related]
18. Structural RNA mimetics: N3'-->P5' phosphoramidate DNA analogs of HIV-1 RRE and TAR RNA form A-type helices that bind specifically to Rev and Tat-related peptides.
Rigl CT; Lloyd DH; Tsou DS; Gryaznov SM; Wilson WD
Biochemistry; 1997 Jan; 36(3):650-9. PubMed ID: 9012680
[TBL] [Abstract][Full Text] [Related]
19. RNA binding by the tat and rev proteins of HIV-1.
Karn J; Dingwall C; Finch JT; Heaphy S; Gait MJ
Biochimie; 1991 Jan; 73(1):9-16. PubMed ID: 1903308
[TBL] [Abstract][Full Text] [Related]
20. Dual-target inhibition of HIV-1 in vitro by means of an adeno-associated virus antisense vector.
Chatterjee S; Johnson PR; Wong KK
Science; 1992 Nov; 258(5087):1485-8. PubMed ID: 1359646
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
